TY - CHAP M1 - Book, Section TI - Special Operative and Multimodal Therapy Considerations in EGJ Cancer Care: Western Viewpoints A1 - Kukar, Moshim A1 - Hochwald, Steven N. A2 - Morita, Shane Y. A2 - Balch, Charles M. A2 - Klimberg, V. Suzanne A2 - Pawlik, Timothy M. A2 - Posner, Mitchell C. A2 - Tanabe, Kenneth K. Y1 - 2018 N1 - T2 - Textbook of Complex General Surgical Oncology AB - Management of Esophago-Gastric Junction (EGJ) cancer with locoregional disease is an area of ongoing discussion and debate, since there is a paucity of randomized trials focusing exclusively on EGJ cancer. Most of the data that guide the multimodality treatment of EGJ adenocarcinoma are derived from trials that involve predominantly gastric or esophageal cancers. Within the trials designed primarily for gastric cancer, patients with EGJ tumors have accounted for only about 20% of all enrollees. There are epidemiologic and pathobiologic differences between EGJ and noncardia gastric adenocarcinomas that raise concern as to whether results from predominantly gastric cancer trials can be extrapolated to EGJ tumors. Similarly, there are histological differences amongst distal esophageal and EGJ tumors. In Siewert’s original description, he recommended that Type 1 EGJ cancers should be treated as esophageal and Type 2 and 3 treated as gastric cancer.1,2 NCCN guidelines based on the seventh edition of the AJCC staging recommends Type 1 and 2 tumors to be staged and treated as esophageal cancer and Type 3 as gastric cancer.3,4 In the following review, we will discuss the available data supporting the operative and multimodality management of EGJ cancers. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1145761446 ER -